ACADIA Pharmaceuticals (DR6) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DR6 Analyst Ratings

Moderate Buy

11 Buy

4 Hold

0 Sell

Based on 15 analysts giving stock ratings to

ACADIA

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DR6 Stock 12 Month Forecast

Average Price Target

€29.32

▲(18.58% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is €29.32 with a high forecast of €43.08 and a low forecast of €21.98. The average price target represents a 18.58% change from the last price of €24.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","44":"€44","23.75":"€23.8","30.5":"€30.5","37.25":"€37.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":43.07574908,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€43.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.324161545714286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€29.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.977423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,23.75,30.5,37.25,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.73,26.141211467692308,27.552422935384616,28.963634403076924,30.37484587076923,31.78605733846154,33.19726880615384,34.608480273846155,36.019691741538466,37.43090320923077,38.842114676923075,40.253326144615386,41.6645376123077,{"y":43.07574908,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.73,25.08339704197802,25.436794083956045,25.790191125934065,26.14358816791209,26.49698520989011,26.850382251868133,27.203779293846154,27.557176335824177,27.910573377802198,28.26397041978022,28.617367461758242,28.970764503736262,{"y":29.324161545714286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.73,24.518263307692308,24.306526615384616,24.094789923076924,23.88305323076923,23.67131653846154,23.459579846153847,23.247843153846155,23.036106461538463,22.82436976923077,22.61263307692308,22.400896384615386,22.189159692307694,{"y":21.977423,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.72,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.45,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.18,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.815,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.515,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.73,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€43.08

Average Price Target€29.32

Lowest Price Target€21.98

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

€36.04→€30.77

Buy

24.42%

Upside

Assigned

09/25/26

Analysts Are Bullish on Top Healthcare Stocks: Arcturus Therapeutics (ARCT), ACADIA Pharmaceuticals (ACAD)

Jason Butler

Citizens JMP

€31.65→€29.01

Buy

17.31%

Upside

Reiterated

09/25/26

Acadia Pharmaceuticals price target lowered to $33 from $36 at CitizensAcadia Pharmaceuticals price target lowered to $33 from $36 at Citizens

David Hoang

Deutsche Bank

€33.41→€27.25

Buy

10.20%

Upside

Reiterated

09/25/26

Acadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche BankAcadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche Bank

Sumant Kulkarni

Canaccord Genuity

€31.65

Buy

27.97%

Upside

Reiterated

09/25/26

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)

Yigal Nochomovitz

Citi

€35.16→€29.01

Buy

17.31%

Upside

Reiterated

09/25/26

Acadia Pharmaceuticals price target lowered to $33 from $40 at CitiAcadia Pharmaceuticals price target lowered to $33 from $40 at Citi

Ananda Ghosh

H.C. Wainwright

€32.53→€29.01

Buy

17.31%

Upside

Reiterated

09/25/26

Acadia price target lowered to $33 from $37 at H.C. WainwrightAcadia price target lowered to $33 from $37 at H.C. Wainwright

Malcolm Hoffman

BMO Capital

€31.65→€29.89

Buy

20.86%

Upside

Reiterated

09/25/26

BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

Tazeen Ahmad

Bank of America Securities

€27.25

Buy

10.20%

Upside

Reiterated

09/24/26

Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)

Sean Laaman

Morgan Stanley

€23.74→€24.61

Hold

-0.47%

Downside

Assigned

08/25/26

Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan StanleyAcadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley

Ashwani Verma

UBS

€39.56→€43.08

Buy

74.18%

Upside

Assigned

08/18/26

Acadia Pharmaceuticals price target raised to $49 from $45 at UBSAcadia Pharmaceuticals price target raised to $49 from $45 at UBS

Ritu Baral

TD Cowen

€32.53

Buy

31.53%

Upside

Assigned

08/05/26

ACADIA Pharmaceuticals: Strong Daybue Outperformance, STIX Uptake, and Raised FY26 Revenue Outlook Support Buy Rating

Paul Matteis

Stifel Nicolaus

€21.98

Hold

-11.13%

Downside

Reiterated

08/05/26

Stifel Nicolaus Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)

Matthew Hershenhorn

Oppenheimer

€20.22→€21.98

Hold

-11.13%

Downside

Reiterated

08/05/26

Acadia Pharmaceuticals price target raised to $25 from $23 at OppenheimerAcadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/04/26

Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)

Brian Abrahams

RBC Capital

€31.65→€32.53

Buy

31.53%

Upside

Assigned

08/04/26

Acadia Pharmaceuticals price target raised to $37 from $36 at RBC CapitalAcadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

€36.04→€30.77

Buy

24.42%

Upside

Assigned

09/25/26

Analysts Are Bullish on Top Healthcare Stocks: Arcturus Therapeutics (ARCT), ACADIA Pharmaceuticals (ACAD)

Jason Butler

Citizens JMP

€31.65→€29.01

Buy

17.31%

Upside

Reiterated

09/25/26

Acadia Pharmaceuticals price target lowered to $33 from $36 at CitizensAcadia Pharmaceuticals price target lowered to $33 from $36 at Citizens

David Hoang

Deutsche Bank

€33.41→€27.25

Buy

10.20%

Upside

Reiterated

09/25/26

Acadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche BankAcadia Pharmaceuticals price target lowered to $31 from $38 at Deutsche Bank

Sumant Kulkarni

Canaccord Genuity

€31.65

Buy

27.97%

Upside

Reiterated

09/25/26

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)

Yigal Nochomovitz

Citi

€35.16→€29.01

Buy

17.31%

Upside

Reiterated

09/25/26

Acadia Pharmaceuticals price target lowered to $33 from $40 at CitiAcadia Pharmaceuticals price target lowered to $33 from $40 at Citi

Ananda Ghosh

H.C. Wainwright

€32.53→€29.01

Buy

17.31%

Upside

Reiterated

09/25/26

Acadia price target lowered to $33 from $37 at H.C. WainwrightAcadia price target lowered to $33 from $37 at H.C. Wainwright

Malcolm Hoffman

BMO Capital

€31.65→€29.89

Buy

20.86%

Upside

Reiterated

09/25/26

BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

Tazeen Ahmad

Bank of America Securities

€27.25

Buy

10.20%

Upside

Reiterated

09/24/26

Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)

Sean Laaman

Morgan Stanley

€23.74→€24.61

Hold

-0.47%

Downside

Assigned

08/25/26

Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan StanleyAcadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley

Ashwani Verma

UBS

€39.56→€43.08

Buy

74.18%

Upside

Assigned

08/18/26

Acadia Pharmaceuticals price target raised to $49 from $45 at UBSAcadia Pharmaceuticals price target raised to $49 from $45 at UBS

Ritu Baral

TD Cowen

€32.53

Buy

31.53%

Upside

Assigned

08/05/26

ACADIA Pharmaceuticals: Strong Daybue Outperformance, STIX Uptake, and Raised FY26 Revenue Outlook Support Buy Rating

Paul Matteis

Stifel Nicolaus

€21.98

Hold

-11.13%

Downside

Reiterated

08/05/26

Stifel Nicolaus Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)

Matthew Hershenhorn

Oppenheimer

€20.22→€21.98

Hold

-11.13%

Downside

Reiterated

08/05/26

Acadia Pharmaceuticals price target raised to $25 from $23 at OppenheimerAcadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/04/26

Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)

Brian Abrahams

RBC Capital

€31.65→€32.53

Buy

31.53%

Upside

Assigned

08/04/26

Acadia Pharmaceuticals price target raised to $37 from $36 at RBC CapitalAcadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

SLDBSolid Biosciences

AHCOAdaptHealth

KNSAKiniksa Pharmaceuticals

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

3 Months

Tessa RomeroJ.P. Morgan

Success Rate

9/13 ratings generated profit

Average Return

+8.76%

Copying Tessa Romero's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.76% per trade.

1 Year

Ami FadiaNeedham

Success Rate

12/18 ratings generated profit

Average Return

+11.99%

Copying Ami Fadia's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +11.99% per trade.

2 Years

Tessa RomeroJ.P. Morgan

Success Rate

12/13 ratings generated profit

Average Return

+24.28%

Copying Tessa Romero's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +24.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DR6 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DR6 has received 33 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. DR6 average Analyst price target in the past 3 months is 29.32.

Each month's total comprises the sum of three months' worth of ratings.

DR6 Financial Forecast

DR6 Earnings Forecast

Next quarter’s earnings estimate for DR6 is €0.17 with a range of €0.10 to €0.25. The previous quarter’s EPS was €0.16. DR6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DR6 has Performed in-line its overall industry.

DR6 Sales Forecast

Next quarter’s sales forecast for DR6 is €291.92M with a range of €285.71M to €299.70M. The previous quarter’s sales results were €270.73M. DR6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DR6 has Performed in-line its overall industry.

DR6 Stock Forecast FAQ

What is DE:DR6’s average 12-month price target, according to analysts?

Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is 29.32.

What is DE:DR6’s upside potential, based on the analysts’ average price target?

ACADIA Pharmaceuticals has 18.58% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACADIA Pharmaceuticals a Buy, Sell or Hold?

ACADIA Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.

What is ACADIA Pharmaceuticals’s share price target?

The average share price target for ACADIA Pharmaceuticals is 29.32. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €43.08 ,and the lowest forecast is €21.98. The average share price target represents 18.58% Increase from the current price of €24.73.

What do analysts say about ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of ACADIA Pharmaceuticals?

To buy shares of DE:DR6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

ACADIA Pharmaceuticals (DR6) Stock Forecast & Price Target

DR6 Analyst Ratings

DR6 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ACADIA Pharmaceuticals

DR6 Analyst Recommendation Trends

DR6 Financial Forecast

DR6 Earnings Forecast

DR6 Sales Forecast

DR6 Stock Forecast FAQ

Detailed List of Analyst Forecasts